Titan Medical (NSDQ:TMDI) announced today that it appointed Stephen Lemieux as its new chief financial officer.
Toronto-based Titan, a robotic surgical technology developer, said in a news release that current CFO Monique Delorme will leave the company, effective immediately. Delorme will remain in an advisory capacity through March 2022 to ensure a smooth transition.
“We would like to thank Monique for her contributions to Titan through a period of great change. Despite the COVID-19 pandemic, during the past 12 months we executed development and license agreements with Medtronic, built out and staffed a research and development facility in Chapel Hill, North Carolina and completed several financings, all of which would not have been possible without Monique’s support,” Titan president & CEO David McNally said in the release. “We are grateful for her commitment and tireless effort and consummate professionalism through this transition period.”
Lemieux joins Titan having spent more than 18 years working for publicly traded companies, mainly focused in the healthcare industry. He has been involved in or led a number of financings, licensing and M&A transactions valued at over $400 million. Most recently, he served as CFO and secretary of NeuPath Health.
“Titan is an innovation leader in robotic single access surgery, and I believe this is an exciting time to be joining Titan as the Enos robotic single access surgical system advances toward several significant milestones. I am pleased to be joining such a talented and dedicated team,” Lemieux said. “I look forward to providing my financial expertise and capital markets experience to support Titan’s goals and upcoming milestones.”
“We are excited to welcome Stephen to Titan,” McNally added. “His wealth of knowledge and experience will be instrumental in helping Titan evolve our financial systems and capital markets strategy, achieve upcoming milestones, and executing upon our vision.”
